The latest price target for Edwards Lifesciences (NYSE:EW) was reported by TD Cowen on June 2, 2026. The analyst firm set a price target for $104.00 expecting EW to rise to within 12 months (a possible 20.96% upside). 67 analyst firms have reported ratings in the last year.

The latest analyst rating for Edwards Lifesciences (NYSE:EW) was provided by TD Cowen, and Edwards Lifesciences maintained their buy rating.

The last upgrade for Edwards Lifesciences Corp happened on January 9, 2026 when TD Cowen raised their price target to $97. TD Cowen previously had a hold for Edwards Lifesciences Corp.

The last downgrade for Edwards Lifesciences Corp happened on October 8, 2025 when Oppenheimer changed their price target from N/A to N/A for Edwards Lifesciences Corp.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Edwards Lifesciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Edwards Lifesciences was filed on June 2, 2026 so you should expect the next rating to be made available sometime around June 2, 2027.

While ratings are subjective and will change, the latest Edwards Lifesciences (EW) rating was a maintained with a price target of $97.00 to $104.00. The current price Edwards Lifesciences (EW) is trading at is $85.98, which is out of the analyst’s predicted range.